Know Cancer

or
forgot password

Phase II Study of Lucanix™ (TGF-beta2 Antisense Gene Modified Allogeneic Tumor Cell Vaccine) in Patients With Stages II-IV Non-Small Cell Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Lung Neoplasm, Carcinoma, Bronchogenic

Thank you

Trial Information

Phase II Study of Lucanix™ (TGF-beta2 Antisense Gene Modified Allogeneic Tumor Cell Vaccine) in Patients With Stages II-IV Non-Small Cell Lung Cancer


This will be a 2-stage, open-label, three-arm, Phase II study. It is designed to evaluate
the efficacy of immunization with increasing doses of an allogeneic tumor cell vaccine,
Lucanix™, in patients with non-curable NSCLC. Patients will be followed for clinical
response, immunogenicity and safety.

Eligible patients will receive 4 monthly intradermal injections with a cell cocktail
comprised of equal numbers of four irradiated allogeneic TGF-beta2 antisense gene modified
NSCLC cell lines. Patients will be randomized to one of the three study cohorts. Patients
will receive 12,500,000, 25,000,000, 50,000,000 gene modified cells respectively. Treated
patients will be evaluated four months after they enter therapy. Patients that respond to
therapy will receive an additional four to twelve injections to evaluate whether their
response to therapy can be amplified. Response, time to tumor progression, and tumor free
survival will be monitored in patients and compared with historical controls and patients
receiving other forms of therapy. Patients will be monitored and evaluated according to
standard evaluation criteria of no response, stable disease, partial response and complete
response.

PRIMARY OBJECTIVE

-Evaluate the ability of increasing doses of Lucanix™, a gene-modified tumor cell vaccine,
to induce tumor response in patients with non-curable NSCLC

SECONDARY OBJECTIVES

- Evaluate the ability of the Lucanix™ vaccination regimen to induce an immune response
(cellular and humoral)

- Estimate the response duration for the Lucanix™ regimen

- Evaluate the effects of repeated inoculations on immune infiltrates

- Evaluate the safety of the Lucanix™ regimen

INCLUSION CRITERIA

- Signed informed consent

- 18 years

- Histologically confirmed non-curable NSCLC with an estimated total tumor burden volume
of less than or equal to 125 cc, confirmed to be stage II, III, or IV.

- Must have completed or refused conventional therapy

- Performance status (ECOG) less than 2.

- Absolute granulocyte count greater than or equal to 1,500/mm3

- Platelet count greater than or equal to 100,000/mm3

- Total Bilirubin less then or equal to 2 mg/dL

- AST and ALT less than or equal to 2x Upper Limit of Normal

- Creatinine less than or equal to 1.5 mg/dL

EXCLUSION CRITERIA

- Concurrent systemic steroids greater than 2 mg prednisone/day

- Prior splenectomy

- Any surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy
or immunotherapy less than 4 weeks of study entry

- Brain metastases or meningeal lymphomatosis unless treated and stable for greater than
or equal to 2 months

- Known HIV positive

- Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled
bacterial, viral, or fungal infections), or other conditions which, in the opinion of
the investigator would compromise protocol objectives.

- Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission for
greater than or equal to 2 years

- Treatment with an investigational drug within 30 days prior to study entry

- History of psychiatric disorder that would impede adherence to protocol

- Pregnant or nursing women or refusal to practice contraception if of reproductive
potential


Inclusion Criteria:



- Signed informed consent

- 18 years

- Histologically confirmed non-curable NSCLC with an estimated total tumor burden
volume of less than or equal to 125 cc, confirmed to be stage II, III, or IV.

- Must have completed or refused conventional therapy

- Performance status (ECOG) less than 2.

- Absolute granulocyte count greater than or equal to 1,500/mm3

- Platelet count greater than or equal to 100,000/mm3

- Total Bilirubin less than or equal to 2 mg/dL

- AST and ALT less than or equal to 2x Upper Limit of Normal

- Creatinine less than or equal to 1.5 mg/Dl

Exclusion Criteria:

- Concurrent systemic steroids greater than 2 mg prednisone/day

- Prior splenectomy

- Any surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy
or immunotherapy less than 4 weeks of study entry

- Brain metastases or meningeal lymphomatosis unless treated and stable for ≥ 2 months

- Known HIV positive

- Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled
bacterial, viral, or fungal infections), or other conditions which, in the opinion of
the investigator would compromise protocol objectives.

- Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission
for greater than or equal to 2 years

- Treatment with an investigational drug within 30 days prior to study entry

- History of psychiatric disorder that would impede adherence to protocol

- Pregnant or nursing women or refusal to practice contraception if of reproductive
potential

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Evaluate the ability of increasing doses of Lucanix™, a gene-modified tumor cell vaccine, to induce tumor response in patients with non-curable NSCLC

Outcome Time Frame:

Week 16, quarterly during treatment and first year of post-intervention follow-up

Safety Issue:

No

Principal Investigator

Habib Fakhrai, PhD

Investigator Role:

Study Director

Investigator Affiliation:

NovaRx Corporation

Authority:

United States: Food and Drug Administration

Study ID:

BB-IND 8868

NCT ID:

NCT01058785

Start Date:

March 2003

Completion Date:

December 2005

Related Keywords:

  • Lung Neoplasm
  • Carcinoma, Bronchogenic
  • Gene therapy
  • Flow cytometry
  • Immunoenzyme technique
  • Laboratory biomarker analysis
  • Tumor cell-derivative vaccine therapy
  • Neoplasms
  • Carcinoma
  • Carcinoma, Bronchogenic
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Mary Crowley Medical Research CenterDallas, Texas  75246
Hoag Cancer CenterNewport Beach, California  92658
Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD, and Janet Burroff MD APMMetairie, Louisiana  70006